Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
US7067313B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 13, 2000 |
| Grant date | Jun 27, 2006 |
| Priority date | — |
| Expiry date | Apr 30, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/36
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention comprises ligands and methods of manufacture thereof as well as pharmaceutical preparations including the ligands. The ligands may be human or humanized monoclonal antibodies and fragments, derivatives and homologs thereof. These may exhibit an unforeseen “plateau effect”, i.e. the achievement of only a partial inactivation of a factor involved in hemostasis, in particular in the coagulation cascade, either individually or in combination even in molar excess. The ligands may bind to a factor or a complex of factors resulting in only partially impairing the function of a physiologically functional site of the said factor or factor complex even in molar excess. This makes the ligands particularly suitable for treating coagulation disorders and resulting thrombotic pathologic conditions while minimizing the risk of bleeding. Particularly useful is a property of ligands in accordance with the present invention to allow some physiological function of the affected site even when the ligand is in molar excess. The ligands may be anti-factor VIII antibodies or antibodies against a factor VIII complex, in particular human or human hybrid monoclonal antibodies which bin…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.